Company: JUNS
Filing Date: 2025-10-28
Form Type: PRER14A
Source: 0001493152-25-019793
Chunk: 63

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-10-28
Form: PRER14A
Chunk 63
---
 ceases to be owned by us, arranging for the assumption of awards, or replacement of awards with new awards based on other property or other securities, by the affected subsidiary or by the entity that controls that subsidiary (as well as any corresponding adjustments to awards that remain based upon our securities). Our Compensation Committee will also make appropriate adjustments and modifications in the terms of any outstanding awards to reflect, or related to, any such events, adjustments, substitutions or changes, including modifications of performance goals and changes in the length of performance periods.

Amendment and Termination

Our Board will have the authority to amend, alter, suspend or terminate the 2025 Plan in whole or in part, in its sole discretion. However, our Board will be required to obtain approval of our stockholders, if required by the exemption from the short-swing profit recovery rules of the Exchange Act, the tax law requirements for “incentive stock options” or any applicable law, regulation or rule, of any amendment of the 2025 Plan that would: (a) increase the maximum number of Shares that may be sold or awarded under the 2025 Plan; (b) decrease the minimum option exercise price or SAR grant price required by the 2025 Plan, except, in the case of (a) or (b), in the event of certain changes in capital of our company (as described above under “— Changes in Capital”); (c) change the class of persons eligible to receive awards under the 2025 Plan; (d) extend the duration of the 2025 Plan or the maximum exercise periods of any options or SARs granted under the 2025 Plan; or (e) otherwise require stockholder approval to comply with applicable laws, regulations or rules. Our Compensation Committee may also amend outstanding awards.

However, no amendment, alteration, suspension or termination of the 2025 Plan or amendment of outstanding awards may materially impair the previously accrued rights of a participant under any outstanding award without his or her written consent, except (a) to comply with the exemption from the short-swing profit recovery rules of the Exchange Act or (b) where our Board or our Compensation Committee determines that the amendment or alteration either (1) is required or advisable to comply with laws, regulations, rules or accounting standards or (2) is not reasonably likely to significantly diminish, without adequate compensation, the benefits provided under an award. Additionally, the provisions of the 2025 Plan described above under “— Change of Control” may not be amended, terminated